16 results about "Myricetin" patented technology

The invention relates to the technical field of traditional Chinese medicines, and discloses application of an active ingredient of shiny-leaved yellowhorn leaves in preparation of a medicine for treating hyperuricemia. The xanthoceras sorbifolia leaf active ingredients comprise quercitrin, rutin and myricetin; the content of quercitrin is 0.2508 mg / g to 0.6719 mg / g, the content of rutin is 0.6707 mg / g to 1.5831 mg / g, and the content of myricetin is 0.8002 mg / g to 3.4858 mg / g. According to the invention, myricetin, quercitrin and rutin are determined as core effective substances of shiny-leaved yellowhorn leaves for treating hyperuricemia for the first time; the multi-target and multi-channel action mechanism is disclosed; meanwhile, network pharmacological analysis shows that the three components have high connectivity in a network and jointly act on key targets such as XOD, ACE, AKR1B1 and TNF, it is prompted that the three components do not act singly, but play a treatment role through multi-target and multi-channel cooperation, the traditional'single target-single drug 'thinking is changed into a'multi-component-multi-target-multi-channel' system regulation mode, and the treatment effect is improved. A new thought is provided for comprehensive treatment of the hyperuricemia.

The invention discloses a Pickering emulsion with stable starch-myricetin composite nanoparticles and a preparation method of the Pickering emulsion, and belongs to the technical field of starch modification and emulsion delivery. Starch and myricetin are combined and compounded, a dynamic high-pressure microjet homogenization technology is introduced, the starch-myricetin composite nano-particles capable of stabilizing Pickering emulsion are obtained through a one-step method, and the application limitation that nano-starch is high in hydrophilicity, high in digestibility and the like is effectively solved; the prepared starch-myricetin composite nanoparticles have the characteristics of high stability and slow digestion function; the Pickering emulsion is prepared by further matching with a compound oil phase of coconut oil and cinnamon essential oil, so that the problem of coconut oil solidification can be effectively solved, and the Pickering emulsion has an antibacterial effect.

The application discloses a three-channel fluorescence sensor array based on sulfur quantum dots and a preparation method and detection application thereof. The sensor array is composed of three kinds of sulfur quantum dots, namely C-SQDs, PSS-SQDs and beta-SQDs. When target objects exist, the three kinds of sensing units generate differentiated fluorescence responses, forming a unique "fingerprint map". By using principal component analysis to analyze the response mode, the array can successfully distinguish between structurally similar baicalein, fiscetin, myricetin, quercetin and rutin in a concentration range of 8.0-56 muM. In addition, the array can also perform semi-quantitative analysis on a single flavone compound in a range of 4.0-56 muM, and the first principal component has a good linear relationship with the logarithm of the concentration of the target object.

The application discloses a research method of a potential protein target point of Guangxi Yaoshan sweet tea against diabetic nephropathy based on proteomics, relates to the technical field of biological medicine, and solves the problem of lacking research on the target point of the action of Yaoshan sweet tea on the prevention and treatment of diabetic nephropathy from the perspective of proteomics. The method comprises the following steps: determining a characteristic active ingredient, namely myricetin, of Yaoshan sweet tea for intervention on diabetic nephropathy, obtaining a PPI network of network pharmacology of the intersection target point of the characteristic active ingredient of Yaoshan sweet tea and diabetic nephropathy; preparing a myricetin solution, preparing a cell disease model and grouping intervention, collecting and pre-treating a cell protein sample, performing mass spectrometry, pre-processing proteomic mass spectrometry data, screening a potential protein target point, identifying and analyzing an expression change trend of the potential protein target point, and analyzing a core protein target point and a key signal path. The application directly locates the key protein target point of Guangxi Yaoshan sweet tea on diabetic nephropathy from a protein expression level, which is more intuitive and more accurate.

The present invention relates to a composition for alleviating skin damage caused by particulate matter (PM), the composition comprising myricetin as an active ingredient. Myricetin, which is an active ingredient of the composition for alleviating skin damage according to the present invention, can effectively reduce oxidative stress caused by PM2.5, endoplasmic reticulum stress and mitochondrial dysfunction, and apoptosis caused by cell exposure to PM2.5. Therefore, the composition comprising myricetin as an active ingredient according to the present invention shows great potential as a therapeutic candidate for treating skin damage caused by PM2.5.

Stabilized oils including an edible oil and an antioxidant composition comprising α-lipoic acid and least one of ascorbic acid, ascorbyl palmitate, green tea extract, lecithin, and rosemary extract or at least one of 1,2,4-benzenetriol, carnosic acid, dihydromyricetin, dihydrorobinetin, epigallocatechin, gallic acid, 3-hydroxytyrosol, myricetin, and nepodin, and methods of preparing such stabilized edible oils. The stabilized oils may have an Oxidative Stability Index (“OSI”) at 110° C. of at least 30 hours.

A nanomaterial is gold or silver nanoparticle having a nanoparticle surface that consists of one or more of the following extracts from sweet gum leaves: shikimic acid, sweet gum leaf family of Catechins, sweet gum leaf family of Quercetin, Sweroside, Afzelechin, p-Coumaric Acid, Epiafzelechin Trimethyl Ether, Myricetin, Naringenin, Phloretin, Procyanidin B1 and related polyphenols, flavonoids and alkaloids. An antiviral / antibacterial agent includes sweet gum mediated silver nanoparticles having a core size and in a concentration having efficacy as an antiviral / antibacterial exceeding a 3 log 10 reduction in viral titer.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

The invention discloses a method for evaluating, regulating and controlling ultraviolet B-band (ultraviolet B, UV-B) irradiation enrichment of grape secondary metabolites on the basis of a microtubulin array. The material is used for evaluating a microtubulin array and preparing a sample solution for determining secondary metabolites by applying a high performance liquid chromatography, and by detecting the enrichment degrees of the cell metabolites of rutin, kaempferol, myricetin and resveratrol before and after irradiation, the microtubulin array can be used for evaluating the microtubulin array and preparing the sample solution for determining the secondary metabolites. The raw materials for preparing food and cosmetics with anti-inflammatory and anti-oxidation effects are obtained. The invention creates a complete method from treatment time and treatment steps of UV-B irradiation of the American sandy grape cell suspension, monitoring of dynamic changes of tubulin and cell morphology indexes, and detection of changes of cell metabolites such as rutin, kaempferol, myricetin and resveratrol before and after irradiation. And a new way is provided for applying the enriched grape natural secondary metabolites to production of food and cosmetics with anti-inflammatory and anti-oxidation effects.

This invention belongs to the field of coking wastewater concentrate treatment, and discloses a coking wastewater membrane concentrate treatment agent and its preparation method. The treatment agent comprises the following raw materials in parts by weight: 5-15 parts ethylenediaminetetraacetic acid, 10-30 parts sodium persulfate, 20-50 parts modified cellulose, and 10-25 parts lime; wherein the modified cellulose is a composite material obtained by reacting cellulose with sulfonated myricetin at a mass ratio of 1:(2-3). The treatment agent of this invention uses modified cellulose obtained by combining cellulose and sulfonated myricetin, which can significantly improve its adsorption performance and complexing ability in wastewater treatment, and enhance its ability to remove organic matter. Through the synergistic effect of multiple components, the treatment agent of this invention can simultaneously and efficiently remove high concentrations of organic matter, high salinity, and high color from coking wastewater membrane concentrate.

The application relates to the fields of biological analysis and biological medicine and functional food technology, and particularly relates to a food source product affinity screening method for reducing blood pressure, a composition and application, the screening method injects a sample of a food source product to be detected into an ACE / ET-1 composite affinity chromatographic column for chromatographic separation, and adopts ELSD to detect the peak time of the food source product to be detected; the food source product is divided into different binding classification according to the peak time difference between the food source product and a negative control group, and the food source product combination of different binding classification is selected to obtain a food source product composition for reducing blood pressure. The application also specifically discloses the screened composition or monomer compound for reducing blood pressure, PCR / WB and HE pathology prove that the composition can down-regulate ACE / ET-1 path-related indexes, and the monomer compounds of myricetin and myricitrin can also down-regulate ACE / ET-1 related mRNA and protein expression.

The application discloses a method for rapidly detecting 30 compounds in tea, such as catechins, flavonoids, anthocyanins, phenolic acids and amino acids, wherein the 30 compounds are gallic acid, theobromine, GC, protocatechuic acid, theophylline, EGC, theanine, chlorogenic acid, caffeine, catechin, syringic acid, caffeic acid, vanillic acid, epicatechin, EGCG, delphinidin, salicylic acid, GCG, p-coumaric acid, cyanidin, ferulic acid, sinapic acid, rutin, ECG, pelargonidin, myricetin, theaflavin, quercetin, apigenin and kaempferol. The application can realize simultaneous rapid qualitative and quantitative detection of the 30 compounds, and provides technical support for development of active substances in tea.

The application discloses a method for preparing high-purity myricetin by using a molecular sieve catalyst, and relates to the technical field of medicine and chemical industry. The method comprises the following steps: step S1, raw material pretreatment; step S2, multi-energy field assisted leaching; step S3, molecular sieve catalysis; and step S4, purification. The method for preparing high-purity myricetin by using a molecular sieve catalyst can safely and efficiently prepare high-purity myricetin with high yield.

The present invention provides compositions that can include naturally derived compounds such as myricetin (or a derivative or salt thereof) or an anthocyanin (or a derivative or salt thereof) or a combination of thereof. The compositions can be used in a variety of applications such as for managing weight, treating a metabolic disorder, maintaining cardiovascular health, reducing systemic inflammation, and / or treating addiction in a subject.

The present invention pertains to the field of medical technology, specifically disclosing the pharmaceutical application of dimyricetin-based diselenide in type II diabetes. After four weeks of continuous administration, compared with the model control group, the test substances DMS-ASD and AQ-C-a demonstrated effects that were basically equivalent to the positive control drug, semaglutide injection, in reducing fasting blood glucose levels after 16 hours of fasting in db / db mice, reducing random blood glucose levels in db / db mice, inhibiting postprandial blood glucose elevations in db / db mice, decreasing the HbA1c content of glycated hemoglobin in db / db mice, and influencing body weight and food intake in db / db mice. The pharmaceutical application of dimyricetin-based diselenide in type II diabetes holds great promise.